Amplify Weight Loss Drug & Treatment ETF (THNR)

THNR Holdings Information

THNR is an equity ETF with a total of 21 individual holdings. The top holdings are Eli Lilly and Company stock at 16.62%, Novo Nordisk at 9.82%, Regeneron Pharmaceuticals at 8.37%, Amgen at 7.30%, and Chugai Pharmaceutical at 7.13%.

• Total Holdings: 21
• Top 10 Percentage: 74.76%
• Asset Class: Equity
• ETF Category: Health
• Assets: 2.85M
• PE Ratio: 19.05

Top 25 Holdings

As of Nov 25, 2025

Filter results

No.	Symbol	Name	% Weight	Shares
1	LLY	Eli Lilly and Company	16.62%	427
2	NVO	Novo Nordisk A/S	9.82%	5,951
3	REGN	Regeneron Pharmaceuticals, Inc.	8.37%	303
4	AMGN	Amgen Inc.	7.30%	610
5	TYO: 4519	Chugai Pharmaceutical Co., Ltd.	7.13%	3,800
6	MRK	Merck & Co., Inc.	5.63%	1,518
7	SWX: ROG	Roche Holding AG	5.21%	383
8	AZN	AstraZeneca PLC	5.21%	1,594
9	ABBV	AbbVie Inc.	4.77%	587
10	PFE	Pfizer Inc.	4.69%	5,200
11	HKG: 1801	Innovent Biologics, Inc.	4.44%	10,500
12	TYO: 4507	Shionogi & Co., Ltd.	4.36%	7,100
13	HKG: 1093	CSPC Pharmaceutical Group Limited	3.50%	100,000
14	HIMS	Hims & Hers Health, Inc.	3.25%	2,497
15	CPH: ZEAL	Zealand Pharma A/S	3.19%	1,130
16	SRRK	Scholar Rock Holding Corporation	1.92%	1,317
17	HKG: 1276	Jiangsu Hengrui Pharmaceuticals Co.,Ltd	1.40%	4,400
18	KRX: 128940	Hanmi Pharm. Co., Ltd.	1.16%	110
19	HKG: 3933	The United Laboratories International Holdings Limited	1.02%	18,000
20	AGPXX	Short-Term Investment Trust - Invesco Government & Agency Portfolio	0.76%	21,588
21	n/a	OTHER ASSETS AND LIABILITIES	0.23%	102,163,710